Story Feb. 6 - X4 Pharmaceuticals: The rare disease biotech is laying off 43 employees—equivalent to 30% of the company’s total staffers—along with the discontinuation of its “research ...

The stock value and growth potential of a biotech firm depend on the type of diseases it treats. This might also include the research that the firm does as it supports other companies, diseases or ...